Monitoring Impurities in Pharmaceutical Products - ICH Q3 requirements

This pharma training will discuss how to monitor impurities in pharmaceutical products as per ICH Q3 A/B requirements and learn how to measure the thresholds to report for regulatory submission.

Why Should You Attend:

Monitoring impurities is considered a critical activity of analytical development in order to ensure the quality of the pharmaceutical products. Current ICH Guidelines indicate that the measurement of impurities should always be conducted for active pharmaceutical ingredient (API) and its drug products. This session will discuss the requirements of ICH Q3A/B for monitoring impurities in API and drug products, practical considerations when examine impurities, how they are reported in regulatory documentation, and key factors to consider when setting impurity specifications.

Areas Covered in the Seminar:

• Understand regulatory expectations.
• Discuss warning letters and citations.
• Understand regulatory requirement guidelines surrounding impurities in API and Drug Products.
• Review ICH Q3A for controlling impurities in API and Q3B for impurities in Drug Products.
• Understand different thresholds to report for regulatory submission.

Who Will Benefit:

To get the most out of the course, we highly recommended that you have at least two years of pharmaceutical analysis or drug development experience.

• R&D analysts
• QA and QC Managers
• Regulatory scientists
• Directors
• Regulators and Researchers who are responsible for providing analytical data pertaining to pharmaceutical products